Overview of Gemcitabine Activity in Advanced Breast Cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 9, 2006, Pages 19-23

  Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; FEMALE; HUMANS; PACLITAXEL; TAXOIDS;

EID: 33745183372     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.020     Document Type: Article

References (16)

1. Possinger K., Kaufmann M., Coleman R., et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10 (1999) 155-162
2. Blackstein M., Vogel C.L., Ambinder R., et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer. A phase II trial. Oncology 62 (2002) 2-8
3. Spielmann M., Llombart-Cussac A., Kalla S., et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60 (2001) 303-307
4. Albain K.S., Nag S., Calderillo-Ruiz G., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC). First report of overall survival. J Clin Oncol 22 (2004) 5s abstr 510
5. Fountzilas G., Nicolaides C., Bafaloukos D., et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer. A Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18 (2000) 503-509
6. Mavroudis D., Malamos N., Alexopoulos A., et al., Greek Breast Cancer Cooperative Group. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine. A multicenter phase II trial. Ann Oncol 10 (1999) 211-215
7. Laufman L.R., Spiridonidis C.H., Pritchard J., et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer. A phase II trial. Ann Oncol 12 (2001) 1259-1264
8. Brandi M., Giotta F., Vici P., et al. Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC). Preliminary results of a multicenter phase II trial of GOIM (Gruppo Oncologico dell'Italia Merdidionale). Proc Am Soc Clin Oncol 20 (2001) 52b abstr 1956
9. Kornek G.V., Haider K., Kwasny W., et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8 (2002) 1051-1056
10. Pelegri A., Calvo L., Mayordomo J.I., et al. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer. Preliminary results from a phase II trial. Semin Oncol 31 suppl 5 (2004) 20-24
11. Chan S., Romieu G., Huober J., et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts). Results of a European phase III study. J Clin Oncol 23 suppl 16 (2005) 581 abstr
12. Colomer R., Llombart A., Lluch A., et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer. Preliminary results of a phase II trial. Semin Oncol 27 suppl 2 (2000) 20-24
13. Sledge G.W. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin Oncol 30 (2003) 19-21
14. Conte P., Salvadori B., Donati S., et al. The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer. Oncology 15 (2001) 41-43
15. Sanchez-Rovira P., Jaen A., Gonzalez E., et al. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology 15 (2001) 44-47
16. Zielinski C., Beslija S., Mrsic-Krmpotic Z., et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 23 (2005) 1401-1408